Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
NOBL vs XBI: how they differ
NOBL and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
ProShares S&P 500 Dividend Aristocrats ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, NOBL and XBI hold 0% of their money in the same securities at the same weight.
| Only in NOBL | Only in XBI |
|---|---|
| INTL BUSINESS MACHINES CORP 1.72% | MODERNA INC 2.87% |
| BECTON DICKINSON AND CO 1.69% | TWIST BIOSCIENCE CORP 1.81% |
| ERIE INDEMNITY COMPANY-CL A 1.69% | HALOZYME THERAPEUTICS INC 1.47% |
| ROPER TECHNOLOGIES INC 1.68% | NATERA INC 1.46% |
| TARGET CORP 1.64% | KYMERA THERAPEUTICS INC 1.45% |
| CHEVRON CORP 1.61% | TRAVERE THERAPEUTICS INC 1.40% |
| GENUINE PARTS CO 1.61% | ROIVANT SCIENCES LTD 1.39% |
| MEDTRONIC PLC 1.61% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026 and Sep 11, 2026.
| NOBL ProShares S&P 500 Dividend Aristocrats ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | ProShares | State Street |
| What it is | S&P 500 Dividend Aristocrats | SPDR S&P Biotech |
| Total return, 1 year | +9.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −8.1 pts | +46.5 pts |
| Expense ratio | 0.35% | 0.35% |
| Already in the S&P 500 | 100.0% | 8.5% |
| Holdings | 69 | 154 |
NOBL in plain words
NOBL is an index equity fund tracking the S&P 500 Dividend Aristocrats. Over the year to Sep 11, 2026 it returned +9.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 11, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 69 positions, with the top ten at 16.5%. It sat 4.8% below its high of Aug 24, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, NOBL or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, NOBL returned +9.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, NOBL or XBI?
- NOBL charges 0.35% a year and XBI charges 0.35%, so NOBL is cheaper. Fees come from each fund's prospectus.
- How much do NOBL and XBI overlap with the S&P 500?
- By their latest filed holdings, 100% of NOBL and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, NOBL against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/nobl-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources